Roundtable Prostate Cancer

GU Oncology Now EditorsRoundtable | April 6, 2022
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
View More
GU Oncology Now EditorsRoundtable | April 6, 2022
Dr. Oliver Sartor and Dr. Rana McKay discuss some limitations (and advantages) of lutetium-177-PSMA.
GU Oncology Now EditorsRoundtable | April 6, 2022
Dr. Oliver Sartor weighs in on lutetium-177-PSMA as an effective therapy for prostate cancer.
GU Oncology Now EditorsRoundtable | April 5, 2022
The palliative benefits of lutetium-177 PSMA are discussed, including reduced symptom burden compared with standard of care.
GU Oncology Now EditorsRoundtable | April 4, 2022
Drs. George and Sprenkle discuss PSMA PET scans, including challenges and the potential of Lutetium-based PSMA treatments.
GU Oncology Now EditorsRoundtable | April 1, 2022
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
GU Oncology Now EditorsRoundtable | December 22, 2021
Drs. Agarwal, Calais, and Tward discuss the use of radiopharmaceutical-based therapeutics in patients with prostate cancer.
GU Oncology Now EditorsRoundtable | December 21, 2021
Drs. Agarwal and Tagawa discuss the VISION trial and how lutetium-177 PSMA-617 will be used to treat metastatic CRPC.
GU Oncology Now EditorsRLT-PSMA | December 17, 2021
Drs. Agarwal and Tagawa discuss PSMA imaging and the future of CT scans in the follow-up of metastatic prostate cancer.
GU Oncology Now EditorsRLT-PSMA | December 17, 2021
Drs. Agarwal and Tward discuss the use of PSMA imaging for oncologists and urologists dealing with localized prostate cancer.
GU Oncology Now EditorsRoundtable | December 16, 2021
Drs. Agarwal and Calais review the basics of PSMA imaging of prostate cancer and what makes it unique.
Advertisement
Advertisement